Driving groundbreaking research. Improving lives.

Helping people with an MPN live a better quality of life as we work toward answers to prevention, progression and a cure for polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF) – blood cancers collectively known as myeloproliferative neoplasms.

MPNRF By the Numbers

$ 0 M

What is Primary Myelofibrosis (MF)?

Primary Myelofibrosis (MF)

PMF is a chronic blood cancer in which excessive scar tissue forms in the bone marrow and impairs its ability to produce normal blood cells.

Learn more about MF

What is Essential Thrombocythemia (ET)?

Essential Thrombocythemia (ET)

Most commonly diagnosed in women over the age of 50, ET is associated with a proliferation of platelet precursors in the bone marrow and complications frequently include blood clotting and/or bleeding.

Learn more about ET

What is Polycythemia Vera (PV)

Polycythemia Vera (PV)

The disease is most common in men over the age of 60, but anyone can develop PV. PV patients typically experience an elevated red blood cell count, an elevated platelet count and an enlarged spleen, especially over time.

Learn more about PV

Recent News

  • Thrive Initiative Press Release

    MPN NEWS | December 14, 2022

    MPN Research Foundation Awards Additional $1.8 Million for Blood Cancer Research into Myeloproliferative Neoplasms Dec. 14, 2022 (Chicago) − MPN Research Foundation (MPNRF) announces its 2022 Thrive Initiative recipients for projects that fill research funding gaps, some of which surfaced due to the pandemic. This $1.8 million in awards is in addition to currently funded… Read More »Thrive Initiative Press Release


    Blood Brothers

    MPN NEWS | December 9, 2022

    Growing up in Czechoslovakia four years apart, Josef and Jaroslav Prchal didn’t always agree on things. And that’s still true today. Yet, independently and together, these two physicians/scientists have made practice-changing marks on the global red blood cell landscape — and particularly on polycythemia vera (PV) − both in the research laboratory and medical clinic.… Read More »Blood Brothers


    Richard T. Silver, MD

    MPN NEWS | September 7, 2022

    Before he helped define criteria for the diagnosis of polycythemia vera (PV) and introduced interferon to treat it; before he chaired the guidelines committee for the treatment of chronic myeloid leukemia (CML) for the American Society of Hematology; and long before his name branded an internationally recognized clinic that specializes in myeloproliferative neoplasms (MPNs); Richard… Read More »Richard T. Silver, MD

  • Ready to do more?

    Julie and her family joined team MPN and created HikeMF to join the fight against MPNs.

    Stay Connected

    With an investment today, you can accelerate research for better outcomes.

    By supporting MPN Research Foundation, you’re also supporting countless doctors and researchers around the world who are working to find a cure for these rare diseases.


    Want to learn more about MPNs? Be the first to know about what’s going on in the PV, ET, and MF community.
    Get our monthly update,
    “Under the Microscope”